the tremendous scientific developments in ctDNA, including genetic and epigenetic alterations, which are detectable in the blood—the so-called liquid biopsy—or multicancer early detection tests, represent a revolution that seems to be rapidly emerging on the horizon.
The potential for circulating tumor DNA (ctDNA) in early diagnosis, screening, and prevention can sometimes be overlooked by the oncology community because many of our patients present in our clinics and academic cancer centers with advanced-stage disease. However, the tremendous scientific developments in ctDNA, including genetic and epigenetic alterations, which are detectable in the blood—the so-called liquid biopsy—or multicancer early detection (MCED) tests, represent a revolution that seems to be rapidly emerging on the horizon.
How many times has a patient asked each of us, “Doctor, don’t you have a blood test for my cancer yet?” Recently, the National Cancer Institute (NCI) established some guidance on the MCED blood screening tests, which have begun to proliferate and are available in clinical trials, large health systems, and, shortly, in the commercial marketplace as a reimbursable test.
Many questions remain: Which is the appropriate at-risk population to be screened for the most efficacious application hat is the important algorithm to investigate when a positive test arises to confirm a true positive Conversely, how does one address a false-positive and avoid the cascade of potential costs, complications, and anxiety associated with false-positives or false-negatives?
Given the 33% reduction in cancer mortality since 1991 that was recently announced in the National Cancer Institute’s annual cancer report to the nation, the screening and prevention fi eld loos to these MCE tests as a dramatic new adjunct to assist in detecting early-stage disease, as opposed to later stages, where the oncology community, unfortunately, sees most of its patients.
Separately, the use of ctNA earlier in tumor surveillance, after definitive therapy to detect tumor recurrence or progression and to monitor efficacy and drug resistance, enables previously unimaginable liuid biopsies that are often obtained by a simple blood draw. Monitoring resistant genomic alterations or, in the case of virus-induced cancers, the recidivistic tumor regrowth after therapy, might permit implementation of more targeted, effective therapies sooner.
Thus, with strong support and advocacy, funding from the NCI, investments from commercial entities in the science and the validation of these tests, and further developments in clinical utility, the early-diagnosis fi eld should accelerate in 2023 and beyond. These much more durable cases that also are easier and less expensive to treat and cure, with higher quality of life and less morbidity, provide a sweet spot, warranting our attention and our participation.
Overcoming Barriers in Cancer Clinical Trials: A Path Forward for Better Patient Care
April 29th 2024Clinical trials play a pivotal role in developing effective therapies, yet their integration is challenged by issues such as insufficient reimbursement structures, misaligned incentives, physician burnout, and a complex regulatory environment.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More